CEAPRO INC.
TSX VENTURE : CZO

CEAPRO INC.

October 13, 2005 16:41 ET

Ceapro to present CeaProve™ at Canadian Diabetes Association conference

EDMONTON, Oct. 13 - Ceapro Inc. (TSX VENTURE:CZO) will make a
poster presentation on CeaProve™ at the Canadian Diabetes Association
conference, to be held in Edmonton, Alberta, October 19-22, 2005. The poster
entitled, "Screening for Diabetes and Pre-Diabetes in the Workplace with
CeaProve™, a Diabetes Test Meal" will be presented on October 20, at
12:30 p.m. and 6:30 pm. The presentation will feature the results of the
premarketing trials conducted in six Edmonton-based corporations, including
EPCOR, Lafarge, Lehigh Inland Cement Ltd., PCL Constructors Inc., TEC
Edmonton, and Waiward Steel Fabricators Ltd. The trials, now successfully
completed, revealed that 97% of participants considered themselves healthy
prior to the study; however CeaProve™ identified that 46% of subjects
tested may be at risk for pre-diabetes.

"Employers are becoming painfully aware of the need to promote a healthy
workforce; they have a vested interest to reduce corporate healthcare costs,"
said Dr. Mark Redmond, Ceapro President and CEO. "Workplace wellness
initiatives provide health information and education to individuals who may be
at high risk for disease but who don't have easy access to screening. This
study has shown that CeaProve™ can be easily integrated into healthy
workplace initiatives for onsite, rapid and simple identification of
individuals who may be at high risk for developing diabetes, and who can then
benefit from early interventions to prevent or delay the onset of the
disease."

The Canadian Diabetes Association/Canadian Society of Endocrinology and
Metabolism Professional Conference and Annual Meetings bring together
educators, clinicians and scientists to share their expertise, ideas and
experiences in diabetes and other endocrine disorders. Program highlights
include nationally and internationally renowned speakers addressing current
diagnosis and treatment issues, interactive workshops, meet the professor
sessions, oral abstract sessions, poster presentations, a trade show and
sponsored social activities. For more information, visit:
http://www.diabetes.ca/Section_Professionals/profconference.asp.

About CeaProve™

CeaProve™ is a simple, rapid point-of-care tool to detect the elevated
blood glucose levels indicative of pre-diabetic and diabetic conditions in a
cost effective manner. CeaProve™ consists of calibrated wafers made from a
proprietary formulation of proteins, fats, and complex carbohydrates that are
consumed with a glass of water after an overnight fast. A quick analysis of
the blood, using one of many standard glucose meters presently on the market,
provides an on-the-spot indication of elevated blood glucose levels. Early
detection means earlier intervention (modification of lifestyle, diet, and/or
medication) to better manage, prevent, or delay diabetes, and mitigate the
effects of diabetes and associated complications. Individuals identified by
CeaProve™ as having pre-diabetes or diabetes are recommended to seek
further diagnosis, treatment, education, and support.

About Ceapro Inc.

Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro's shares trade on the TSX Venture Exchange
under the symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares outstanding: 36,757,485. Recent close: $0.38.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.

Contact Information

  • Dr. Mark Redmond, President and CEO, Ceapro
    Inc., Telephone: (780) 421-4555